Targeting localized immune suppression within the tumor through repeat cycles of immune cell-oncolytic virus combination therapy

Molecular Therapy

Volumn 18, Issue 9, 2010, Pages 1698-1705

  Thorne, Stephen H ^a   Liang, Wenchun ^b   Sampath, Padma ^a   Schmidt, Tobi ^b   Sikorski, Rachel ^a   Beilhack, Andreas ^c   Contag, Christopher H ^b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b STANFORD UNIVERSITY   (United States)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; ONCOLYTIC VIRUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER INFILTRATION; CANCER TISSUE; CELL THERAPY; CONTROLLED STUDY; EFFECTOR CELL; IMMUNE DEFICIENCY; IMMUNIZATION; IMMUNOCOMPETENT CELL; LYMPHOCYTE SUBPOPULATION; MOUSE; NONHUMAN; SOLID TUMOR;

MUS;

EID: 77956267058     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.140     Document Type: Article

References (32)

1. Guo, ZS, Thorne, SH and Bartlett, DL (2008). Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochim Biophys Acta 1785: 217-231.
2. Kirn, DH and Thorne, SH (2009). Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer 9: 64-71.
3. Park, BH, Hwang, T, Liu, TC, Sze, DY, Kim, JS, Kwon, HC et al. (2008). Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol 9: 533-542.
4. Liu, TC, Hwang, TH, Bell, JC and Kirn, DH (2008). Translation of targeted oncolytic virotherapeutics from the lab into the clinic, and back again: a high-value iterative loop. Mol Ther 16: 1006-1008.
5. Liu, TC, Galanis, E and Kirn, D (2007). Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol 4: 101-117.
6. Hu, JC, Coffin, RS, Davis, CJ, Graham, NJ, Groves, N, Guest, PJ et al. (2006). A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 12: 6737-6747.
7. Lorence, RM, Roberts, MS, ONeil, JD, Groene, WS, Miller, JA, Mueller, SN et al. (2007). Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus. Curr Cancer Drug Targets 7: 157-167.
8. Kumar, S, Gao, L, Yeagy, B and Reid, T (2008). Virus combinations and chemotherapy for the treatment of human cancers. Curr Opin Mol Ther 10: 371-379.
9. Chang, CL, Ma, B, Pang, X, Wu, TC and Hung, CF (2009). Treatment with cyclooxygenase-2 inhibitors enables repeated administration of vaccinia virus for control of ovarian cancer. Mol Ther 17: 1365-1372.
10. Fulci, G, Breymann, L, Gianni, D, Kurozomi, K, Rhee, SS, Yu, J et al. (2006). Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci USA 103: 12873-12878.
11. Lun, XQ, Jang, JH, Tang, N, Deng, H, Head, R, Bell, JC et al. (2009). Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide. Clin Cancer Res 15: 2777-2788.
12. Kirn, DH, Wang, Y, Liang, W, Contag, CH and Thorne, SH (2008). Enhancing poxvirus oncolytic effects through increased spread and immune evasion. Cancer Res 68: 2071-2075.
13. Qiao, J, Kottke, T, Willmon, C, Galivo, F, Wongthida, P, Diaz, RM et al. (2008). Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy. Nat Med 14: 37-44.
14. Gulley, JL, Arlen, PM, Tsang, KY, Yokokawa, J, Palena, C, Poole, DJ et al. (2008). Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin Cancer Res 14: 3060-3069.
15. Johnson, RS, Walker, AI and Ward, SJ (2009). Cancer vaccines: will we ever learn? Expert Rev Anticancer Ther 9: 67-74.
16. Elkord, E, Dangoor, A, Burt, DJ, Southgate, TD, Daayana, S, Harrop, R et al. (2009). Immune evasion mechanisms in colorectal cancer liver metastasis patients vaccinated with TroVax (MVA-5T4). Cancer Immunol Immunother 58: 1657-1667.
17. Thorne, SH, Negrin, RS and Contag, CH (2006). Synergistic antitumor effects of immune cell-viral biotherapy. Science 311: 1780-1784.
18. Thorne, SH and Contag, CH (2007). Combining immune cell and viral therapy for the treatment of cancer. Cell Mol Life Sci 64: 1449-1451.
19. Thorne, SH and Contag, CH (2008). Integrating the biological characteristics of oncolytic viruses and immune cells can optimize therapeutic benefits of cell-based delivery. Gene Ther 15: 753-758.
20. Thorne, SH, Hwang, TH, OGorman, WE, Bartlett, DL, Sei, S, Kanji, F et al. (2007). Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. J Clin Invest 117: 3350-3358.
21. Luker, KE, Hutchens, M, Schultz, T, Pekosz, A and Luker, GD (2005). Bioluminescence imaging of vaccinia virus: effects of interferon on viral replication and spread. Virology 341: 284-300.
22. Kirn, DH, Wang, Y, Le Boeuf, F, Bell, J and Thorne, SH (2007). Targeting of interferonbeta to produce a specific, multi-mechanistic oncolytic vaccinia virus. PLoS Med 4: e353.
23. Ong, HT, Hasegawa, K, Dietz, AB, Russell, SJ and Peng, KW (2007). Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies. Gene Ther 14: 324-333.
24. Power, AT, Wang, J, Falls, TJ, Paterson, JM, Parato, KA, Lichty, BD et al. (2007). Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity. Mol Ther 15: 123-130.
25. Prestwich, RJ, Ilett, EJ, Errington, F, Diaz, RM, Steele, LP, Kottke, T et al. (2009). Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication. Clin Cancer Res 15: 4374-4381.
26. Qiao, J, Wang, H, Kottke, T, Diaz, RM, Willmon, C, Hudacek, A et al. (2008). Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors. Gene Ther 15: 604-616.
27. Marshall, JL, Hoyer, RJ, Toomey, MA, Faraguna, K, Chang, P, Richmond, E et al. (2000). Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 18: 3964-3973.
28. McCart, JA, Ward, JM, Lee, J, Hu, Y, Alexander, HR, Libutti, SK et al. (2001). Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res 61: 8751-8757.
29. Lu, PH and Negrin, RS (1994). A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 153: 1687-1696.
30. Cao, YA, Bachmann, MH, Beilhack, A, Yang, Y, Tanaka, M, Swijnenburg, RJ et al. (2005). Molecular imaging using labeled donor tissues reveals patterns of engraftment, rejection, and survival in transplantation. Transplantation 80: 134-139.
31. Okabe, M, Ikawa, M, Kominami, K, Nakanishi, T and Nishimune, Y (1997). Green mice as a source of ubiquitous green cells. FEBS Lett 407: 313-319.
32. Hadjantonakis, AK, Macmaster, S and Nagy, A (2002). Embryonic stem cells and mice expressing different GFP variants for multiple non-invasive reporter usage within a single animal. BMC Biotechnol 2: 11.